Sartorius Stedim Biotech SA DIM

Stock XPAR Rating as of Oct 1, 2026

€208.20 +2.00 (0.97%)

As of Oct 2, 2026, 3:35:27 PM Delayed Price Closed

Company Report

Sartorius Stedim Biotech: A Pureplay Bet on Biopharma Recovery

Max Jousma Sep 1, 2026

Sartorius Stedim Biotech, a subsidiary of Sartorius AG, is a leading provider of bioprocessing equipment and consumables. It offers a comprehensive portfolio that spans the full spectrum of upstream and downstream processes required for biologics manufacturing. Its ability to deliver end-to-end solutions and focus as a pure-play biopharmaceutical equipment supplier distinguish SSB from more-diversified competitors. The company reinforces its competitive edge by leading the market in bioreactors, a core component of the biomanufacturing process.

Read Analysis

Price vs Fair Value

View History

DIM is trading at a LOCK|RgjCf<z premium.

Price

€206.20

Oct 1, 2026

Fair Value

zV@

May 7, 2025

Uncertainty

LOCK|QJ

1-Star Price: LOCK|G.T
5-Star Price: LOCK|Q.>&
Economic Moat: LOCK|@l
Capital Allocation: LOCK|<rd<^T

Bulls Say, Bears Say

Bulls

SSB's CGT product portfolio allows the company to capitalize on long-term growth, should these therapies achieve widespread adoption.

Bears

The high growth in the biopharma market increases the risk of greater competition from better-capitalized peers that have a broader product offering.

Trading Information

Previous Close Price: €206.20
Day Range: €204.20–211.20
52-Week Range: €150.00–223.00
Bid/Ask: €207.80 / €209.80
Shares Outstanding: 97.29M
Market Cap: €20.26B
Volume/Avg: 98,529 / 86,803

Key Statistics

Price/Earnings (Normalized): 51.64
Price/Sales: 6.67
Dividend Yield (Trailing): 0.33%
Dividend Yield (Forward): 0.33%
Dividend Payment Schedule: Apr
Total Yield: 0.33%

Company Profile

Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.

Sector: Healthcare
Industry: Medical Instruments & Supplies
Stock Style Box: Mid Core
Total Number of Employees: 10,477
Website: https://www.sartorius.com

Competitors

Valuation

Metric	DIM	MRK	A
Price/Earnings (Normalized)	51.64	16.67	27.50
Price/Book Value	4.73	1.94	6.38
Price/Sales	6.67	2.77	6.41
Price/Cash Flow	32.97	12.84	24.91

Price/Earnings

DIM

MRK

Financial Strength

Metric	DIM	MRK	A
Quick Ratio	0.48	0.99	1.41
Current Ratio	1.16	1.69	2.05
Interest Coverage	4.24	7.22	16.08

Quick Ratio

DIM

MRK

Profitability

Metric	DIM	MRK	A
Return on Assets (Normalized)	5.40%	4.75%	13.27%
Return on Equity (Normalized)	10.62%	8.32%	24.92%
Return on Invested Capital (Normalized)	7.74%	6.65%	16.95%

Return on Assets

DIM

MRK

Medical Instruments & Supplies Industry Comparables

Screen With Investor

Name	Capital Allocation	Economic Moat	Market Cap
Intuitive Surgical Inc ISRG	LOCK\|Rqk!?n<	LOCK\|#CK	$138B
Becton Dickinson & Co BDX	LOCK\|Jss	LOCK\|k#?p	$48B
Medline Inc Ordinary Shares - Class A MDLN	LOCK\|rZN^F<	LOCK\|@>xp?	$31B
ResMed Inc RMD	LOCK\|@!q&T<%	LOCK\|<<n$#	$31B
Alcon Inc ALC	LOCK\|q!g<C^	LOCK\|Zp!F	$31B
West Pharmaceutical Services Inc WST	LOCK\|F%%fB!Y$	LOCK\|w&@	$26B
Solventum Corp SOLV	LOCK\|v@>RXfZ	LOCK\|h%q	$15B
Baxter International Inc BAX	LOCK\|q@	LOCK\|yN>#M	$12B
The Cooper Companies Inc COO	LOCK\|Nkq<WB	LOCK\|ZVl#g	$11B
Repligen Corp RGEN	LOCK\|SQG%bq#	LOCK\|>&d?y	$10B